Itraconazole has been evaluated across numerous clinical trials spanning Early Phase 1 through Phase 4, addressing fungal infections in HIV patients, solid tumors, and drug-drug interactions in healthy volunteers. Prominently supported by pharmaceutical developers and institutional sponsors, research ranges from completed pivotal studies to actively recruiting Phase 1 and Phase 2 trials evaluating pharmacokinetic modulation and oncologic efficacy.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT07261150 | NOT_YET_RECRUITING | Histoplasmosis |
University of Minnesota |
2026-09-15 | PHASE3 |
| NCT07283497 | RECRUITING | Bronchiectasis; Fungal Infection of Upper Respiratory Tract |
Mayo Clinic |
2026-08-17 | PHASE4 |
| NCT06732388 | RECRUITING | Barrett Esophagus; Clinical Stage I Esophageal Adenocarcinoma AJCC v8; Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8; Esophageal Adenocarcinoma |
National Cancer Institute (NCI) |
2026-06-23 | PHASE2 |
| NCT06400472 | RECRUITING | Ovarian Neoplasms; Endometrial Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Triple Negative Breast Neoplasms; Pancreatic Neoplasm; Colorectal Neoplasms |
Eli Lilly and Company |
2024-05-20 | PHASE1 |
| NCT05563766 | RECRUITING | Esophageal Adenocarcinoma; Esophageal Squamous Cell Carcinoma; Gastroesophageal Junction Carcinoma |
VA Office of Research and Development |
2024-10-01 | PHASE2 |
| NCT04067336 | ACTIVE_NOT_RECRUITING | Advanced Malignant Neoplasm; Acute Myeloid Leukemia; Mixed Lineage Leukemia; Mixed Lineage Acute Leukemia; Acute Leukemia of Ambiguous Lineage; Mixed Phenotype Acute Leukemia; Acute Lymphoblastic Leukemia |
Kura Oncology, Inc. |
2019-09-12 | PHASE1; PHASE2 |
| NCT03460977 | RECRUITING | Metastatic Castration Resistant Prostate Cancer (mCRPC); Small Cell Lung Cancer (SCLC); Follicular Lymphoma (FL) |
Pfizer |
2018-04-17 | PHASE1 |
| NCT07070232 | RECRUITING | Advanced Solid Tumor |
BioNTech SE |
2025-08-12 | PHASE1; PHASE2 |
| NCT05914116 | RECRUITING | Advanced Solid Tumors |
DualityBio Inc. |
2023-08-17 | PHASE1; PHASE2 |
| NCT05384626 | RECRUITING | Locally Advanced Solid Tumor; Metastatic Solid Tumor |
Nuvalent Inc. |
2022-06-09 | PHASE1; PHASE2 |
| NCT07402915 | RECRUITING | Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal |
AstraZeneca |
2026-01-26 | PHASE1 |
| NCT06084481 | RECRUITING | Hepatocellular Carcinoma; Pancreatic Ductal Adenocarcinoma; Biliary Tract Cancers; Esophageal Squamous Cell Carcinoma; Triple Negative Breast Cancer; Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer; Head and Neck Squamous-Cell Carcinoma; Platinum Resistant High Grade Epithelial Ovarian Cancer |
AbbVie |
2023-11-09 | PHASE1 |
| NCT05150691 | RECRUITING | HER2-positive Advanced Solid Tumor |
DualityBio Inc. |
2022-01-31 | PHASE1; PHASE2 |
| NCT07797478 | RECRUITING | Healthy Volunteers |
Genentech, Inc. |
2026-08-28 | PHASE1 |
| NCT03656081 | RECRUITING | Chronic Pulmonary Aspergillosis |
Poitiers University Hospital |
2018-12-19 | PHASE3 |
| NCT07395024 | ACTIVE_NOT_RECRUITING | Healthy Volunteer |
Astellas Pharma Global Development, Inc. |
2026-02-03 | PHASE1 |
| NCT07341672 | NOT_YET_RECRUITING | Healthy Adult Subject |
Sunshine Lake Pharma Co., Ltd. |
2026-12-31 | PHASE1 |
| NCT07438886 | NOT_YET_RECRUITING | Healthy Volunteer |
Advenchen Laboratories Nanjing Ltd. |
2026-03-02 | PHASE1 |
| NCT07800897 | NOT_YET_RECRUITING | Healthy Female Adults |
Bristol-Myers Squibb |
2026-08-26 | PHASE1 |
| NCT07675239 | NOT_YET_RECRUITING | Tinea Corporis |
Pak Emirates Military Hospital |
2026-10-01 | PHASE4 |
| NCT07764692 | NOT_YET_RECRUITING | Healthy Participants |
Jiangsu Hansoh Pharmaceutical Co., Ltd. |
2026-08-01 | PHASE1 |
| NCT07339722 | RECRUITING | Healthy |
Eli Lilly and Company |
2026-01-15 | PHASE1 |
| NCT07071532 | NOT_YET_RECRUITING | Bipolar Disorder |
AbbVie |
2026-08-21 | PHASE1 |
| NCT05444946 | RECRUITING | Chronic Pulmonary Aspergillosis; Allergic Bronchopulmonary Aspergillosis |
Post Graduate Institute of Medical Education and Research, Chandigarh |
2022-06-15 | |
| NCT07768111 | NOT_YET_RECRUITING | Drug Interaction Research |
Chengdu Zenitar Biomedical Technology Co., Ltd |
2026-10-30 | PHASE1 |
| NCT07620041 | NOT_YET_RECRUITING | Refractory or Relapsed Solid Tumors |
Qilu Pharmaceutical Co., Ltd. |
2026-06-05 | PHASE1 |
| NCT06300138 | RECRUITING | Sporotrichosis |
First Hospital of China Medical University |
2024-03-15 | |
| NCT07134465 | ENROLLING_BY_INVITATION | Healthy Subjects |
Haisco Pharmaceutical Group Co., Ltd. |
2025-08-11 | PHASE1 |
| NCT07783503 | NOT_YET_RECRUITING | Healthy Participants |
Novartis Pharmaceuticals |
2026-08-27 | PHASE1 |
| NCT07766369 | NOT_YET_RECRUITING | Healthy Volunteers |
Eisai Inc. |
2026-08-12 | PHASE1 |
| NCT07775261 | NOT_YET_RECRUITING | Healthy Participants |
H. Lundbeck A/S |
2026-08-27 | PHASE1 |
| NCT07357610 | RECRUITING | Healthy Adult Participants |
Jiangsu Simcere Pharmaceutical Co., Ltd. |
2026-01-05 | PHASE1 |
| NCT07685600 | RECRUITING | Healthy |
AstraZeneca |
2026-07-30 | PHASE1 |
| NCT07661108 | ACTIVE_NOT_RECRUITING | Healthy |
Merck Sharp & Dohme LLC |
2026-06-30 | PHASE1 |
| NCT07774325 | NOT_YET_RECRUITING | Healthy |
Boehringer Ingelheim |
2026-09-01 | PHASE1 |
| NCT03458221 | RECRUITING | Recurrent Ovarian Cancer; Signal Transduction Pathway Deregulation; Therapy-Associated Cancer |
Gynaecologisch Oncologisch Centrum Zuid |
2023-01-31 | PHASE2; PHASE3 |
| NCT07800429 | NOT_YET_RECRUITING | Healthy Participants |
Vaderis Therapeutics AG |
2026-09 | PHASE1 |
| NCT07590102 | RECRUITING | Healthy Volunteers |
BeOne Medicines |
2026-06-04 | PHASE1 |
| NCT07734441 | RECRUITING | Seborrheic Dermatitis |
Combined Military Hospital (CMH) institute of Medical Sciences Bahawalpur Pakistan |
2026-01-07 | EARLY_PHASE1 |
| NCT07599761 | ACTIVE_NOT_RECRUITING | Healthy Volunteers |
AbbVie |
2026-05-07 | PHASE1 |
| NCT07649954 | RECRUITING | Healthy Volunteer |
AbbVie |
2026-06-23 | PHASE1 |
| NCT07435194 | ACTIVE_NOT_RECRUITING | Healthy |
Merck Sharp & Dohme LLC |
2026-03-06 | PHASE1 |
| NCT07186452 | RECRUITING | Advanced Solid Tumors |
Hansoh BioMedical R&D Company |
2025-09-23 | PHASE1 |
| NCT07535970 | NOT_YET_RECRUITING | Healthy Participants |
Jiangsu Hansoh Pharmaceutical Co., Ltd. |
2026-04-30 | PHASE1 |
| NCT06154447 | COMPLETED | Cystic Fibrosis |
Vertex Pharmaceuticals Incorporated |
2023-12-12 | PHASE1 |
| NCT07592572 | COMPLETED | Healthy |
Eli Lilly and Company |
2026-05-20 | PHASE1 |
| NCT06485505 | RECRUITING | Onychomycosis |
Zagazig University |
2024-07-12 | PHASE1 |
| NCT07374224 | RECRUITING | Clinical Pharmacology |
Guangzhou Lupeng Pharmaceutical Company LTD. |
2026-03-05 | PHASE1 |
| NCT07575945 | COMPLETED | Healthy Participant |
Pfizer |
2026-05-05 | PHASE1 |
| NCT04018872 | RECRUITING | Esophagus Adenocarcinoma; Esophagus Squamous Cell Carcinoma; Gastroesophageal Junction Adenocarcinoma |
Dallas VA Medical Center |
2019-06-24 | PHASE2 |
| NCT06447402 | UNKNOWN | Chronic Pulmonary Aspergillosis; CPA; Aspergilloma |
Post Graduate Institute of Medical Education and Research, Chandigarh |
2024-06-03 | PHASE3 |
| NCT07548606 | COMPLETED | Healthy |
Merck Sharp & Dohme LLC |
2026-05-11 | PHASE1 |
| NCT06174922 | RECRUITING | Allergic Bronchopulmonary Aspergillosis |
Post Graduate Institute of Medical Education and Research, Chandigarh |
2023-12-01 | PHASE3 |
| NCT07550621 | NOT_YET_RECRUITING | Healthy Volunteers (HV) |
MindRank AI Ltd |
2026-05-06 | PHASE1 |
| NCT06909162 | COMPLETED | Healthy Participants |
Incyte Corporation |
2025-05-05 | PHASE1 |
| NCT07449390 | COMPLETED | Healthy Participants |
Acesion Pharma |
2026-04-01 | PHASE1 |
| NCT07331792 | NOT_YET_RECRUITING | Pityriasis Versicolor |
Combined Military Hospital Abbottabad |
2026-02-02 | PHASE1; PHASE2 |
| NCT07242781 | TERMINATED | Healthy Volunteers |
Celgene |
2025-12-15 | PHASE1 |
| NCT07242703 | NOT_YET_RECRUITING | Fungal Resistance |
Cairo University |
2025-12-01 | |
| NCT07429331 | COMPLETED | Healthy Volunteers |
Cascade Pharmaceuticals, Inc |
2026-03-09 | PHASE1 |
| NCT07308652 | COMPLETED | Healthy |
Boehringer Ingelheim |
2026-02-09 | PHASE1 |
| NCT07039877 | RECRUITING | Acute Lymphobkastic Leukemia; Acute Lymphoblastic Leukaemia Recurrent; Philadelphia Chromosome Negative ALL |
Hospital Universitario Dr. Jose E. Gonzalez |
2025-01-02 | PHASE2 |
| NCT07335419 | COMPLETED | Healthy Adult Participants |
Pfizer |
2026-01-02 | PHASE1 |
| NCT07342153 | RECRUITING | Tinea Corporis; Dermatophytosis |
Urooj Fatima |
2025-11-01 | PHASE4 |
| NCT06746064 | COMPLETED | Pulmonary Fibrosis |
Chiesi Farmaceutici S.p.A. |
2025-01-13 | PHASE1 |
| NCT06942936 | COMPLETED | Healthy Participants |
AstraZeneca |
2025-05-28 | PHASE1 |
| NCT07211425 | COMPLETED | Healthy |
Boehringer Ingelheim |
2025-10-08 | PHASE1 |
| NCT06698926 | COMPLETED | Healthy Volunteer |
AbbVie |
2024-11-11 | PHASE1 |
| NCT05156892 | ACTIVE_NOT_RECRUITING | Ovarian Cancer |
Anthony Joshua, FRACP |
2022-09-04 | PHASE1 |
| NCT07697157 | COMPLETED | Health, Subjective |
Hutchmed |
2025-03-01 | PHASE1 |
| NCT06922344 | RECRUITING | Pityriasis Versicolor |
Khyber Teaching Hospital |
2025-03-01 | PHASE4 |
| NCT06160713 | UNKNOWN | Bronchiectasis; Bronchiectasis Adult |
Post Graduate Institute of Medical Education and Research, Chandigarh |
2023-12-01 | PHASE3 |
| NCT07229560 | COMPLETED | Breast Cancer |
Shandong Suncadia Medicine Co., Ltd. |
2025-11-26 | PHASE1 |
| NCT07184203 | RECRUITING | Tinea Capitis |
Alexandria University |
2025-03-09 | |
| NCT07066722 | COMPLETED | HIV Infections |
ViiV Healthcare |
2025-07-07 | PHASE1 |
| NCT07160738 | COMPLETED | Healthy Adults |
Pfizer |
2025-09-22 | PHASE1 |
| NCT06919991 | COMPLETED | Healthy Participants |
Arcus Biosciences, Inc. |
2025-05-02 | PHASE1 |
| NCT06710990 | COMPLETED | Advanced Breast Cancer |
Jiangsu HengRui Medicine Co., Ltd. |
2025-02-17 | PHASE1 |
| NCT06906809 | COMPLETED | Healthy Volunteers |
BeiGene |
2025-04-03 | PHASE1 |
| NCT06701136 | NOT_YET_RECRUITING | Rifampicin-Resistant Pulmonary Tuberculosis Patients |
Shanghai Jiatan Pharmatech Co., Ltd |
2025-05-12 | PHASE1 |
| NCT07068256 | COMPLETED | Tinea Capitis |
Muhammad Aamir Latif |
2025-04-01 | |
| NCT07018635 | COMPLETED | Healthy Participants |
Incyte Corporation |
2025-07-16 | PHASE1 |
| NCT06579300 | TERMINATED | Healthy Volunteer |
AbbVie |
2024-09-04 | PHASE1 |
| NCT07056842 | COMPLETED | Obesity &Amp; Overweight |
Vincentage Pharma Co., Ltd |
2025-07-20 | PHASE1 |
| NCT06945276 | COMPLETED | COVID-19 |
National Institute of Allergy and Infectious Diseases (NIAID) |
2025-05-13 | PHASE1 |
| NCT07420894 | COMPLETED | Dermatophytosis; Trichophyton Infection; Resistant Dermatophyte Infection |
Multan Medical And Dental College |
2025-01-29 | |
| NCT06965881 | TERMINATED | Tuberous Sclerosis Complex (TSC); Focal Cortical Dysplasia; Other Neurological Disorders |
GRIN Therapeutics, Inc. |
2025-05-08 | PHASE1 |
| NCT06672900 | ACTIVE_NOT_RECRUITING | Healthy Volunteer |
Aligos Therapeutics |
2025-01-09 | PHASE1 |
| NCT06787131 | COMPLETED | Healthy |
Lomond Therapeutics Holdings, Inc. |
2024-05-21 | PHASE1 |
| NCT07069933 | NOT_YET_RECRUITING | Acute Myeloid Leukemia |
Mansoura University |
2025-07 | PHASE2 |
| NCT06399315 | COMPLETED | AML |
Lomond Therapeutics Holdings, Inc. |
2023-07-28 | PHASE1 |
| NCT06809608 | COMPLETED | Healthy Participants |
Hoffmann-La Roche |
2025-02-13 | PHASE1 |
| NCT06847464 | COMPLETED | RSV Infection; Drug Drug Interaction (DDI) |
Enanta Pharmaceuticals, Inc |
2025-01-27 | PHASE1 |
| NCT06837142 | COMPLETED | Healthy Male Subjects |
Taisho Pharmaceutical Co., Ltd. |
2025-03-11 | PHASE1 |
| NCT06846528 | COMPLETED | Healthy Participants |
AstraZeneca |
2025-02-26 | PHASE1 |
| NCT06541678 | COMPLETED | Healthy |
Pfizer |
2024-12-23 | PHASE1 |
| NCT06662773 | UNKNOWN | Healthy |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2024-11 | PHASE1 |
| NCT06706869 | COMPLETED | Healthy |
Pfizer |
2024-12-11 | PHASE1 |
| NCT06671405 | COMPLETED | Dyslipidaemia |
AstraZeneca |
2024-09-25 | PHASE1 |
| NCT06690138 | COMPLETED | Healthy Participants |
Genentech, Inc. |
2024-11-15 | PHASE1 |
| NCT06205381 | COMPLETED | Healthy Participants |
Aeovian Pharmaceuticals, Inc. |
2024-01-31 | PHASE1 |
| NCT06722430 | COMPLETED | Healthy Volunteer |
AbbVie |
2024-11-13 | PHASE1 |
| NCT06677996 | COMPLETED | Healthy Volunteer |
Immunome, Inc. |
2024-11-11 | PHASE1 |
| NCT06597500 | COMPLETED | Pulmonary Disease, Chronic Obstructive |
GlaxoSmithKline |
2024-09-30 | PHASE1 |
| NCT06658964 | NOT_YET_RECRUITING | ADPKD (autosomal Dominant Polycystic Kidney Disease) |
Jemincare |
2024-11-05 | PHASE1 |
| NCT06586606 | COMPLETED | Alzheimer's Disease |
Merck Sharp & Dohme LLC |
2024-10-03 | PHASE1 |
| NCT06562088 | UNKNOWN | Healthy Adult Subject |
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. |
2024-08-16 | PHASE1 |
| NCT06619951 | COMPLETED | Locally Advanced or Metastatic Solid Tumor |
Jiangsu vcare pharmaceutical technology co., LTD |
2024-09-18 | PHASE1 |
| NCT06362642 | COMPLETED | Healthy Volunteers |
PMV Pharmaceuticals, Inc |
2024-03-28 | PHASE1 |
| NCT06543043 | COMPLETED | Not Determined |
BeiGene |
2024-08-19 | PHASE1 |
| NCT06494644 | COMPLETED | Healthy Participants |
AstraZeneca |
2024-07-23 | PHASE1 |
| NCT06492525 | UNKNOWN | Healthy |
Betta Pharmaceuticals Co., Ltd. |
2024-07 | PHASE1 |
| NCT05591560 | UNKNOWN | Ovarian Carcinoma |
Tanta University |
2022-10 | |
| NCT06379958 | UNKNOWN | Pharmacokinetics |
Modern Biosciences Ltd |
2024-04-08 | PHASE1 |
| NCT06589635 | COMPLETED | Healthy Adults |
Jiaxing AnDiCon Biotech Co.,Ltd |
2024-07-16 | PHASE1 |
| NCT06363630 | COMPLETED | Healthy Volunteers |
Celgene |
2024-04-23 | PHASE1 |
| NCT06644326 | COMPLETED | Healthy |
ABLi Therapeutics, Inc. |
2023-06-21 | PHASE1 |
| NCT05679388 | TERMINATED | Prostate Cancer; Prostate Cancer Metastatic; Prostate Adenocarcinoma |
University of Chicago |
2023-02-13 | PHASE1 |
| NCT06495944 | COMPLETED | Healthy Adults |
Corcept Therapeutics |
2024-05-31 | PHASE1 |
| NCT06406400 | TERMINATED | Opioid Use Disorder |
AstraZeneca |
2024-05-13 | PHASE1 |
| NCT06719557 | COMPLETED | Healthy |
Merck Sharp & Dohme LLC |
2024-05-20 | PHASE1 |
| NCT05372367 | COMPLETED | Solid Tumors |
Boehringer Ingelheim |
2022-08-11 | PHASE1 |
| NCT06232109 | COMPLETED | Drug Drug Interaction |
Asceneuron S.A. |
2024-02-22 | PHASE1 |
| NCT06392659 | COMPLETED | Pain |
Vertex Pharmaceuticals Incorporated |
2024-05-02 | PHASE1 |
| NCT06344936 | UNKNOWN | Chronic Kidney Disease(CKD) |
Shandong Suncadia Medicine Co., Ltd. |
2024-04 | PHASE1 |
| NCT06345794 | COMPLETED | Healthy |
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company |
2024-04-03 | PHASE1 |
| NCT06357520 | COMPLETED | Healthy Participants |
AstraZeneca |
2024-04-16 | PHASE1 |
| NCT06348888 | COMPLETED | Advanced Non-small Cell Lung Cancer; EGFR Mutation; HER2 Mutation; Healthy Volunteers |
Bayer |
2024-04-10 | PHASE1 |
| NCT06332053 | UNKNOWN | Healthy Subjects |
Shouyao Holdings (Beijing) Co. LTD |
2024-04-01 | PHASE1 |
| NCT04824417 | COMPLETED | Chronic Pulmonary Aspergillosis |
Post Graduate Institute of Medical Education and Research, Chandigarh |
2021-03-01 | PHASE3 |
| NCT06348290 | UNKNOWN | Solid Tumor, Adult |
Jemincare |
2024-04-01 | PHASE1 |
| NCT02675452 | TERMINATED | Relapsed or Refractory Multiple Myeloma; Relapsed or Refractory Acute Myeloid Leukemia |
Amgen |
2016-06-13 | PHASE1 |
| NCT06170723 | COMPLETED | Healthy Participants |
Celgene |
2024-03-18 | PHASE1 |
| NCT06255951 | COMPLETED | NSCLC |
TYK Medicines, Inc |
2024-03-12 | PHASE1 |
| NCT06194864 | COMPLETED | Drug Interaction |
Emalex Biosciences Inc. |
2024-01-18 | PHASE1 |
| NCT06294561 | COMPLETED | Non Small Cell Lung Cancer |
Shenzhen TargetRx Co., Ltd. |
2024-03-04 | PHASE1 |
| NCT05563766 | Not yet recruiting | Esophageal Adenocarcinoma|Esophageal Squamous Cell Carcinoma|Gastroesophageal Junction Carcinoma |
VA Office of Research and Development|Durham VA Health Care System|VA Palo Alto Health Care System|Portland VA Medical Center|VA Puget Sound Health Care System|Michael E. DeBakey VA Medical Center|VA Boston Healthcare System |
2024-05-01 | Phase 2 |
| NCT06173596 | COMPLETED | Healthy |
Alexion Pharmaceuticals, Inc. |
2024-01-10 | PHASE1 |
| NCT05840952 | COMPLETED | COVID-19 |
Aligos Therapeutics |
2023-07-04 | PHASE1 |
| NCT06357520 | Recruiting | Healthy Participants |
AstraZeneca |
2024-04-16 | Phase 1 |
| NCT06348888 | Recruiting | Advanced Non-small Cell Lung Cancer|EGFR Mutation|HER2 Mutation|Healthy Volunteers |
Bayer |
2024-04-10 | Phase 1 |
| NCT02875223 | TERMINATED | Lymphoma, Non-Hodgkin; Neoplasms |
Celgene |
2016-08-31 | PHASE1 |
| NCT06362642 | Recruiting | Healthy Volunteers |
PMV Pharmaceuticals Inc |
2024-03-28 | Phase 1 |
| NCT05049525 | TERMINATED | Crohn's Disease; Inflammatory Bowel Diseases |
Montreal Heart Institute |
2022-02-22 | PHASE2 |
| NCT05667662 | TERMINATED | ABPA |
Pulmatrix Inc. |
2023-02-01 | PHASE2 |
| NCT05609253 | ACTIVE_NOT_RECRUITING | Barrett Oesophagitis With Dysplasia |
University of Kansas Medical Center |
2022-09-14 | EARLY_PHASE1 |
| NCT06162169 | COMPLETED | Healthy Subjects |
Allist Pharmaceuticals, Inc. |
2023-11-25 | PHASE1 |
| NCT06105255 | COMPLETED | Healthy Male |
InventisBio Co., Ltd |
2023-05-24 | PHASE1 |
| NCT06024915 | COMPLETED | Myelofibrosis |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2023-09-21 | PHASE1 |
| NCT06688045 | COMPLETED | Healthy |
Merck Sharp & Dohme LLC |
2023-10-30 | PHASE1 |
| NCT06165822 | UNKNOWN | Advanced Malignant Neoplasm |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2023-12 | PHASE1 |
| NCT05902728 | COMPLETED | NSCLC |
Shanghai Henlius Biotech |
2023-07-04 | PHASE1 |
| NCT04886323 | COMPLETED | Malassezia Folliculitis |
The Second Hospital of Anhui Medical University |
2022-08-03 | |
| NCT06106334 | COMPLETED | Obesity; Healthy Volunteers |
Shionogi |
2023-11-15 | PHASE1 |
| NCT05954624 | COMPLETED | Drug Drug Interaction |
Guangdong Raynovent Biotech Co., Ltd |
2023-07-10 | PHASE1 |
| NCT05965219 | COMPLETED | Healthy Volunteers |
Cerevel Therapeutics, LLC |
2023-08-15 | PHASE1 |
| NCT06041438 | COMPLETED | Healthy |
Boehringer Ingelheim |
2023-09-29 | PHASE1 |
| NCT05965583 | COMPLETED | Healthy |
Boehringer Ingelheim |
2023-08-02 | PHASE1 |
| NCT05691699 | COMPLETED | Healthy Volunteer |
AbbVie |
2023-01-03 | PHASE1 |
| NCT05932303 | COMPLETED | Healthy Participants |
Bristol-Myers Squibb |
2023-07-12 | PHASE1 |
| NCT05699993 | COMPLETED | Healthy Subjects |
Innovent Biologics (Suzhou) Co. Ltd. |
2023-03-10 | PHASE1 |
| NCT05881980 | UNKNOWN | Tinea Corporis; Tinea Cruris; Tinea Faciei; Dermatophytoses |
Dhaka Medical College |
2023-05 | PHASE2; PHASE3 |
| NCT05684718 | COMPLETED | Bacterial Infections |
BioVersys AG |
2023-02-01 | PHASE1 |
| NCT05949385 | COMPLETED | Pharmacokinetics |
Nanjing Zenshine Pharmaceuticals |
2023-07-02 | PHASE1 |
| NCT05994807 | COMPLETED | Healthy Volunteers |
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company |
2023-08-08 | PHASE1 |
| NCT05789342 | COMPLETED | Healthy Volunteers |
Jiangxi Qingfeng Pharmaceutical Co. Ltd. |
2023-02-15 | PHASE1 |
| NCT06089733 | COMPLETED | Healthy Subjects |
Abbisko Therapeutics Co, Ltd |
2023-04-11 | PHASE1 |
| NCT03513211 | COMPLETED | Prostate Cancer |
St Vincent's Hospital, Sydney |
2018-08-23 | PHASE1; PHASE2 |
| NCT05860933 | COMPLETED | Healthy |
Eli Lilly and Company |
2023-05-08 | PHASE1 |
| NCT05822440 | COMPLETED | Healthy |
Pfizer |
2023-04-13 | PHASE1 |
| NCT05129033 | UNKNOWN | Allergic Bronchopulmonary Aspergillosis |
Shanghai Zhongshan Hospital |
2021-11-15 | |
| NCT05833139 | COMPLETED | Healthy |
Boehringer Ingelheim |
2023-04-14 | PHASE1 |
| NCT06087055 | COMPLETED | Healthy Participant |
Fujian Akeylink Biotechnology Co., Ltd. |
2023-05-12 | PHASE1 |
| NCT05745701 | COMPLETED | Healthy |
Pfizer |
2023-02-22 | PHASE1 |
| NCT05538312 | COMPLETED | Healthy |
Pfizer |
2023-02-23 | PHASE1 |
| NCT05573724 | COMPLETED | Advanced Solid Malignancies |
AstraZeneca |
2022-11-07 | PHASE1 |
| NCT05586568 | UNKNOWN | Healthy Subjects |
Xuanzhu Biopharmaceutical Co., Ltd. |
2022-11-15 | PHASE1 |
| NCT04537715 | COMPLETED | All Malignancies; Advanced Malignancies; Hematologic Malignancy; Solid Tumor; Follicular Lymphoma (FL); Non-Hodgkin Lymphoma (NHL); Diffuse Large B-Cell Lymphoma (DLBCL); Epithelioid Sarcoma (ES); Synovial Sarcoma; Renal Medullary Carcinoma; Mesothelioma; Rhabdoid Tumor |
Epizyme, Inc. |
2020-04-23 | PHASE1 |
| NCT05348096 | UNKNOWN | Chronic Graft-versus-host-disease |
Hospital Universitario Dr. Jose E. Gonzalez |
2022-04-01 | PHASE2 |
| NCT05685719 | COMPLETED | COVID-19 Pneumonia |
Zhejiang ACEA Pharmaceutical Co. Ltd. |
2023-01-04 | PHASE1 |
| NCT05518734 | COMPLETED | Pain |
Vertex Pharmaceuticals Incorporated |
2022-09-17 | PHASE1 |
| NCT05635305 | COMPLETED | Healthy Volunteers |
Global Antibiotics Research and Development Partnership |
2022-11-09 | PHASE1 |
| NCT05720767 | COMPLETED | Relapsed or Refractory Lymphoma |
Hutchmed |
2022-11-04 | PHASE1 |
| NCT05665647 | COMPLETED | Healthy Volunteers |
Jiangsu Simcere Pharmaceutical Co., Ltd. |
2022-12-29 | PHASE1 |
| NCT05048615 | COMPLETED | AML |
Hospital Universitario Dr. Jose E. Gonzalez |
2021-07-26 | PHASE2 |
| NCT05551897 | COMPLETED | Healthy Subjects |
AstraZeneca |
2022-10-04 | PHASE1 |
| NCT05594602 | COMPLETED | COVID-19 |
Enanta Pharmaceuticals, Inc |
2022-10-06 | PHASE1 |
| NCT07542847 | COMPLETED | Healthy Volunteers |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2022-09-19 | PHASE1 |
| NCT05304533 | COMPLETED | Healthy Participants |
Bristol-Myers Squibb |
2022-04-21 | PHASE1 |
| NCT05389722 | COMPLETED | Healthy Volunteers |
Bristol-Myers Squibb |
2022-06-09 | PHASE1 |
| NCT05549531 | COMPLETED | Healthy |
Idorsia Pharmaceuticals Ltd. |
2022-10-01 | PHASE1 |
| NCT04586920 | TERMINATED | Healthy |
Eli Lilly and Company |
2020-10-20 | PHASE1 |
| NCT05486949 | COMPLETED | Healthy Subjects |
Dizal Pharmaceuticals |
2022-07-27 | PHASE1 |
| NCT05862714 | COMPLETED | Tinea Versicolor |
Combined Military Hospital Abbottabad |
2022-03-01 | PHASE1 |
| NCT04564612 | COMPLETED | Healthy Volunteers |
Biogen |
2020-09-28 | PHASE1 |
| NCT04809649 | WITHDRAWN | Coccidioidomycosis; Valley Fever |
George R Thompson |
2021-05-15 | PHASE2 |
| NCT05578950 | COMPLETED | Onychomycosis |
Combined Military Hospital Abbottabad |
2022-03-01 | PHASE1 |
| NCT05236543 | COMPLETED | Healthy Volunteers |
AstraZeneca |
2022-02-18 | PHASE1 |
| NCT05602597 | COMPLETED | Relapsed or Refractory Lymphoma |
Hutchmed |
2022-06-01 | PHASE1 |
| NCT05631678 | COMPLETED | Locally Advanced or Metastatic NSCLC |
Jiangsu Aosaikang Pharmaceutical Co., Ltd. |
2022-06-06 | PHASE1 |
| NCT05437094 | COMPLETED | Clinical Pharmacology; Pharmacokinetics; Cardiovascular Diseases; Heart Failure |
Cardurion Pharmaceuticals, Inc. |
2022-06-27 | PHASE1 |
| NCT05076955 | UNKNOWN | Diabetic Foot Ulcer |
University of Mississippi Medical Center |
2021-03-31 | EARLY_PHASE1 |
| NCT05404724 | COMPLETED | Rheumatoid Arthritis |
Jiangsu HengRui Medicine Co., Ltd. |
2022-06-25 | PHASE1 |
| NCT05162222 | COMPLETED | Healthy Participants |
Bristol-Myers Squibb |
2021-12-15 | PHASE1 |
| NCT05203822 | COMPLETED | Healthy |
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany |
2022-01-21 | PHASE1 |
| NCT05797753 | COMPLETED | Amyotrophic Lateral Sclerosis; Healthy Volunteer |
Sanofi |
2022-02-18 | PHASE1 |
| NCT04959266 | TERMINATED | Advanced Solid Tumours |
AstraZeneca |
2021-06-28 | PHASE1 |
| NCT05418582 | COMPLETED | Healthy Subjects |
Dizal Pharmaceuticals |
2022-01-25 | PHASE1 |
| NCT04035187 | COMPLETED | Fungal Infection |
University of Maryland, Baltimore |
2020-02-10 | PHASE4 |
| NCT05084651 | COMPLETED | Malaria |
Novartis Pharmaceuticals |
2021-11-18 | PHASE1 |
| NCT05255276 | COMPLETED | Healthy Adults |
Mirati Therapeutics Inc. |
2022-02-02 | PHASE1 |
| NCT04956627 | COMPLETED | Healthy Participants |
Bristol-Myers Squibb |
2021-07-28 | PHASE1 |
| NCT07001501 | COMPLETED | Healthy |
Henan Genuine Biotech Co., Ltd. |
2022-02-21 | PHASE1 |
| NCT04908800 | COMPLETED | Healthy |
Kyorin Pharmaceutical Co.,Ltd |
2021-05-27 | PHASE1 |
| NCT05063318 | COMPLETED | Advanced Solid Tumors |
PharmaMar |
2020-10-07 | PHASE1 |
| NCT04840888 | COMPLETED | Healthy |
Eli Lilly and Company |
2021-04-26 | PHASE1 |
| NCT05205447 | TERMINATED | Healthy |
Eli Lilly and Company |
2022-01-05 | PHASE1 |
| NCT05272683 | COMPLETED | Healthy |
Lakefront Biotherapeutics NV |
2022-02-28 | PHASE1 |
| NCT04880980 | COMPLETED | Dermatophyte Infection; Terbinafine Adverse Reaction; Itraconazole Adverse Reaction |
Pak Emirates Military Hospital |
2021-03-15 | PHASE3 |
| NCT05057949 | COMPLETED | Healthy Volunteers |
Sunshine Lake Pharma Co., Ltd. |
2021-11-24 | PHASE1 |
| NCT05928988 | COMPLETED | Healthy |
Jiangsu HengRui Medicine Co., Ltd. |
2022-01-04 | PHASE1 |
| NCT05359055 | COMPLETED | Drug Drug Interaction |
Shanghai Pharmaceuticals Holding Co., Ltd |
2021-12-13 | PHASE1; PHASE2 |
| NCT06246695 | COMPLETED | Healthy Volunteers |
Suzhou Zelgen Biopharmaceuticals Co.,Ltd |
2021-10-27 | PHASE1 |
| NCT05316857 | COMPLETED | Healthy Person |
Beijing InnoCare Pharma Tech Co., Ltd. |
2021-12-16 | PHASE1 |
| NCT05567484 | COMPLETED | Onychomychosis |
Combined Military Hospital Abbottabad |
2021-05-01 | PHASE1 |
| NCT03827278 | UNKNOWN | Talaromyces in Human Immunodeficiency Virus Negative; To Compare Voriconazole and Amphotericin Sequential Itraconazole Therapy; To Dynamically Monitor the Anti-Interferon-γ Autoantibodies |
Guangxi Medical University |
2018-12-30 | |
| NCT05154136 | COMPLETED | Healthy Participants |
Arcus Biosciences, Inc. |
2021-10-20 | PHASE1 |
| NCT05357820 | COMPLETED | Solid Tumor |
Nuvation Bio Inc. |
2021-07-19 | PHASE1 |
| NCT03340220 | COMPLETED | Healthy Volunteers |
Xenon Pharmaceuticals Inc. |
2017-11-13 | PHASE1 |
| NCT05064449 | COMPLETED | Healthy Volunteers |
Takeda |
2021-10-14 | PHASE1 |
| NCT05069870 | UNKNOWN | Healthy Subjects |
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. |
2021-06-07 | PHASE1 |
| NCT04962022 | COMPLETED | Healthy Participant |
Pfizer |
2021-07-20 | PHASE1 |
| NCT02699723 | WITHDRAWN | Skin Basal Cell Carcinoma |
Jean Yuh Tang |
2020-12 | EARLY_PHASE1 |
| NCT04154800 | COMPLETED | Health Participants |
Bristol-Myers Squibb |
2019-12-06 | PHASE1 |
| NCT04942652 | COMPLETED | Achlorhydria |
Seoul National University Hospital |
2021-07-13 | PHASE1 |
| NCT04481100 | UNKNOWN | Esophageal Neoplasm; Esophageal Diseases; Esophageal Squamous Cell Carcinoma |
Hangzhou Cancer Hospital |
2020-10-01 | PHASE2 |
| NCT04619251 | COMPLETED | Healthy |
Boehringer Ingelheim |
2020-11-13 | PHASE1 |
| NCT03920527 | COMPLETED | Chronic Pulmonary Aspergillosis |
Post Graduate Institute of Medical Education and Research, Chandigarh |
2019-07-01 | PHASE3 |
| NCT04981704 | COMPLETED | Healthy |
Spectrum Pharmaceuticals, Inc |
2021-04-08 | PHASE1 |
| NCT04604795 | COMPLETED | Celiac Disease; Coeliac Disease |
GlaxoSmithKline |
2020-11-04 | PHASE1 |
| NCT04783753 | COMPLETED | Hepatitis B |
Enanta Pharmaceuticals, Inc |
2020-11-05 | PHASE1 |
| NCT04845646 | COMPLETED | Healthy; NAFLD |
Gannex Pharma Co., Ltd. |
2021-03-16 | PHASE1 |
| NCT03086226 | COMPLETED | Mycetoma |
Drugs for Neglected Diseases |
2017-05-09 | PHASE2 |
| NCT04808648 | UNKNOWN | Healthy Male Volunteers |
Nanjing Sanhome Pharmaceutical, Co., Ltd. |
2021-04-06 | PHASE1 |
| NCT04464577 | WITHDRAWN | Healthy Participants |
Bristol-Myers Squibb |
2021-04-01 | PHASE1 |
| NCT04268394 | COMPLETED | Healthy Volunteer |
Celgene |
2020-03-13 | PHASE1 |
| NCT03572049 | COMPLETED | Invasive Fungal Infections |
University of Alabama at Birmingham |
2018-09-17 | PHASE2; PHASE3 |
| NCT04843449 | COMPLETED | Healthy |
Ascletis Pharmaceuticals Co., Ltd. |
2021-04-04 | PHASE1 |
| NCT04714073 | COMPLETED | Healthy |
Boehringer Ingelheim |
2021-02-11 | PHASE1 |
| NCT04739774 | COMPLETED | Chronic Obstructive Pulmonary Disease |
Chiesi Farmaceutici S.p.A. |
2021-02-22 | PHASE1 |
| NCT04716894 | COMPLETED | Healthy |
Boehringer Ingelheim |
2021-02-01 | PHASE1 |
| NCT04743414 | COMPLETED | Healthy Volunteers |
Concert Pharmaceuticals |
2021-03-02 | PHASE1 |
| NCT04712396 | COMPLETED | Healthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer) |
AstraZeneca |
2021-02-01 | PHASE1 |
| NCT04584515 | COMPLETED | Solid Tumor |
Impact Therapeutics, Inc. |
2020-11-02 | PHASE1 |
| NCT04290390 | COMPLETED | Women; Contraception |
TherapeuticsMD |
2020-02-12 | PHASE1 |
| NCT04410094 | COMPLETED | Healthy |
Janssen Research & Development, LLC |
2020-09-14 | PHASE1 |
| NCT03972748 | UNKNOWN | Basal Cell Carcinoma; Hedgehog Pathway |
Hospital de Clinicas de Porto Alegre |
2018-01-05 | |
| NCT04606537 | COMPLETED | Healthy; Drug Drug Interaction |
KBP Biosciences |
2020-10-24 | PHASE1 |
| NCT04577378 | UNKNOWN | Covid19 |
Kafrelsheikh University |
2020-10-20 | PHASE2 |
| NCT04557163 | COMPLETED | Healthy Subjects |
Taisho Pharmaceutical Co., Ltd. |
2020-10-13 | PHASE1 |
| NCT05134337 | COMPLETED | Healthy Volunteers |
Loxo Oncology, Inc. |
2020-02-12 | PHASE1 |
| NCT04557397 | COMPLETED | Drug Drug Interaction |
Hutchison Medipharma Limited |
2020-09-02 | PHASE1 |
| NCT04627129 | COMPLETED | Healthy Adult Subjects |
Jiangsu HengRui Medicine Co., Ltd. |
2020-06-01 | PHASE1 |
| NCT04312282 | TERMINATED | Advanced Solid Tumors |
Odonate Therapeutics, Inc. |
2020-03-06 | PHASE1 |
| NCT04372407 | COMPLETED | Healthy |
Hutchison Medipharma Limited |
2020-07-09 | PHASE1 |
| NCT04411030 | COMPLETED | Healthy Volunteer |
Astex Pharmaceuticals, Inc. |
2020-05-20 | PHASE1 |
| NCT04455100 | COMPLETED | Health, Subjective |
Jiangsu HengRui Medicine Co., Ltd. |
2020-07-17 | PHASE1 |
| NCT00585195 | COMPLETED | Non-Small Cell Lung Cancer ALK-positive; Non-Small Cell Lung Cancer c-Met Dependent; Non-Small Cell Lung Cancer ROS Marker Positive; Systemic Anaplastic Large-Cell Lymphoma; Advanced Malignancies Except Leukemia |
Pfizer |
2006-04-19 | PHASE1 |
| NCT04423601 | COMPLETED | Healthy Subjects |
Jiangsu HengRui Medicine Co., Ltd. |
2020-06-10 | PHASE1 |
| NCT04405323 | COMPLETED | Healthy |
H. Lundbeck A/S |
2020-05-20 | PHASE1 |
| NCT04135833 | COMPLETED | NSCLC |
Beta Pharma, Inc. |
2019-12-12 | PHASE1 |
| NCT03960606 | TERMINATED | Allergic Bronchopulmonary Aspergillosis |
Pulmatrix Inc. |
2019-07-31 | PHASE2 |
| NCT06090123 | COMPLETED | Erectile Dysfunction |
Vigonvita Life Sciences |
2020-01-01 | PHASE1 |
| NCT04709081 | COMPLETED | Healthy |
Alexion Pharmaceuticals, Inc. |
2019-12-22 | PHASE1 |
| NCT03923010 | TERMINATED | Mycoses |
Janssen Research & Development, LLC |
2019-08-06 | PHASE4 |
| NCT04208373 | COMPLETED | Healthy |
Janssen Research & Development, LLC |
2019-12-20 | PHASE1 |
| NCT04166669 | COMPLETED | Fungal Infection |
Basilea Pharmaceutica |
2019-11-12 | PHASE1 |
| NCT04171739 | COMPLETED | Healthy |
F2G Ltd |
2019-11-18 | PHASE1 |
| NCT04014361 | TERMINATED | Healthy |
Eli Lilly and Company |
2019-08-09 | PHASE1 |
| NCT04142762 | COMPLETED | Chronic Hepatitis B |
Assembly Biosciences |
2019-10-18 | PHASE1 |
| NCT04121910 | COMPLETED | Solid Tumour |
AstraZeneca |
2019-11-07 | PHASE1 |
| NCT04090047 | COMPLETED | Heathy Participants |
Pfizer |
2019-09-24 | PHASE1 |
| NCT05568082 | COMPLETED | Healthy Participants |
Amgen |
2019-12-03 | PHASE1 |
| NCT03664115 | UNKNOWN | Lung Cancer |
Ain Shams University |
2018-07-02 | PHASE2 |
| NCT04138836 | COMPLETED | Healthy Participants |
Bridge Biotherapeutics, Inc. |
2019-09-17 | PHASE1 |
| NCT03994211 | COMPLETED | Solid Tumor |
BeiGene |
2019-05-29 | PHASE1 |
| NCT04479891 | COMPLETED | Healthy Subjects |
Jiangsu HengRui Medicine Co., Ltd. |
2019-09-18 | PHASE1 |
| NCT03945539 | COMPLETED | Healthy |
Janssen Sciences Ireland UC |
2019-05-15 | PHASE1 |
| NCT03631602 | UNKNOWN | IFD Post-HSCT |
Fujian Medical University |
2017-10-01 | PHASE2; PHASE3 |
| NCT04011241 | COMPLETED | Healthy |
Boehringer Ingelheim |
2019-07-24 | PHASE1 |
| NCT02749513 | UNKNOWN | Esophageal Cancer |
Dallas VA Medical Center |
2016-01 | EARLY_PHASE1 |
| NCT03081702 | COMPLETED | Platinum-resistant Epithelial Ovarian Cancer |
University Health Network, Toronto |
2017-07-25 | PHASE1; PHASE2 |
| NCT04008186 | COMPLETED | Healthy Adult Subjects |
Biogen |
2019-06-14 | PHASE1 |
| NCT03928327 | COMPLETED | Healthy Volunteers |
Millennium Pharmaceuticals, Inc. |
2019-05-02 | PHASE1 |
| NCT03991312 | COMPLETED | Healthy Volunteers |
Agios Pharmaceuticals, Inc. |
2019-06-20 | PHASE1 |
| NCT03950960 | COMPLETED | Healthy Participants |
Bristol-Myers Squibb |
2019-05-02 | PHASE1 |
| NCT03512548 | COMPLETED | Healthy |
Corcept Therapeutics |
2018-04-10 | PHASE1 |
| NCT03890887 | COMPLETED | Healthy |
Boehringer Ingelheim |
2019-04-12 | PHASE1 |
| NCT03892499 | COMPLETED | Healthy |
Cyclerion Therapeutics |
2019-05-03 | PHASE1 |
| NCT03843151 | COMPLETED | Healthy |
Boehringer Ingelheim |
2019-03-19 | PHASE1 |
| NCT02285283 | TERMINATED | Chronic Rhinosinusitis |
The University of Texas Health Science Center, Houston |
2014-11 | PHASE2; PHASE3 |
| NCT03103646 | COMPLETED | Cytochrome P450 Interaction |
H. Lundbeck A/S |
2017-03-28 | PHASE1 |
| NCT03821493 | COMPLETED | Healthy Participants |
Pfizer |
2019-02-21 | PHASE1 |
| NCT03843060 | COMPLETED | Heart Failure With Preserved Ejection Fraction (HFpEF) |
AstraZeneca |
2019-02-22 | PHASE1 |
| NCT03782662 | COMPLETED | Respiratory Syncytial Virus Infections |
Pfizer |
2018-11-07 | PHASE1 |
| NCT03774576 | COMPLETED | Healthy Volunteers |
Hoffmann-La Roche |
2018-12-17 | PHASE1 |
| NCT03782987 | COMPLETED | Healthy |
Boehringer Ingelheim |
2019-01-10 | PHASE1 |
| NCT03789890 | COMPLETED | Drug Interactions |
Bayer |
2019-01-08 | PHASE1 |
| NCT02354261 | COMPLETED | Basal Cell Carcinoma in Basal Cell Nevus Syndrome |
HedgePath Pharmaceuticals, Inc. |
2015-08-07 | PHASE2 |
| NCT03792139 | COMPLETED | Healthy |
Eli Lilly and Company |
2019-01-08 | PHASE1 |
| NCT03530995 | COMPLETED | Drug-drug Interaction; Autoimmune Diseases; Fibrotic Disease |
Kadmon Corporation, LLC |
2018-04-09 | PHASE1 |
| NCT02120677 | COMPLETED | Basal Cell Carcinoma |
Johns Hopkins University |
2014-05 | EARLY_PHASE1 |
| NCT03755778 | COMPLETED | RSV Infection |
Enanta Pharmaceuticals, Inc |
2018-11-29 | PHASE1 |
| NCT03471455 | UNKNOWN | Tinea |
Post Graduate Institute of Medical Education and Research, Chandigarh |
2018-04 | PHASE2 |
| NCT03723395 | COMPLETED | Drug-drug Interaction |
Seagen Inc. |
2018-09-17 | PHASE1 |
| NCT03722173 | COMPLETED | Healthy |
Boehringer Ingelheim |
2018-11-13 | PHASE1 |
| NCT03579719 | COMPLETED | Healthy Volunteers |
Hoffmann-La Roche |
2018-07-10 | PHASE1 |
| NCT06421714 | COMPLETED | Healthy Volunteers |
Genzyme, a Sanofi Company |
2018-08-16 | PHASE1 |
| NCT03614455 | COMPLETED | Pharmacokinetics |
Daiichi Sankyo |
2018-07-13 | EARLY_PHASE1 |
| NCT02770378 | COMPLETED | Glioblastoma |
University of Ulm |
2016-11 | PHASE1; PHASE2 |
| NCT03383692 | COMPLETED | Neoplasm Metastasis |
Daiichi Sankyo Co., Ltd. |
2018-01-12 | PHASE1 |
| NCT02608034 | COMPLETED | Metastatic Melanoma, BRAF V600 Mutation Positive |
Genentech, Inc. |
2016-05-26 | PHASE1 |
| NCT03624959 | COMPLETED | Healthy Volunteer |
Celgene |
2018-06-20 | PHASE1 |
| NCT03535662 | COMPLETED | Pharmacokinetic Study in Healthy Male Volunteers |
Nerre Therapeutics Ltd. |
2018-06-08 | PHASE1 |
| NCT05338489 | COMPLETED | Healthy |
Eli Lilly and Company |
2018-05-11 | PHASE1 |
| NCT03403439 | COMPLETED | Healthy |
Boehringer Ingelheim |
2018-05-03 | PHASE1 |
| NCT03555617 | COMPLETED | Inflammatory Bowel Disease |
Theravance Biopharma |
2018-06-13 | PHASE1 |
| NCT03499106 | COMPLETED | Healthy |
Cyclerion Therapeutics |
2018-04-12 | PHASE1 |
| NCT02357836 | COMPLETED | Non-small Cell Lung Cancer |
University of Texas Southwestern Medical Center |
2015-06 | EARLY_PHASE1 |
| NCT03479411 | COMPLETED | Asthma |
Pulmatrix Inc. |
2018-02-09 | PHASE1 |
| NCT02824042 | COMPLETED | Medical Oncology |
Bayer |
2016-09-07 | PHASE1 |
| NCT04110834 | COMPLETED | Tinea Versicolor |
Sara Botros |
2018-02-15 | PHASE2 |
| NCT03515382 | COMPLETED | Healthy |
Lakefront Biotherapeutics NV |
2018-03-16 | PHASE1 |
| NCT03498170 | COMPLETED | Interaction |
Mereo BioPharma |
2018-03-19 | PHASE1 |
| NCT02895529 | TERMINATED | Hematologic Neoplasms |
Xian-Janssen Pharmaceutical Ltd. |
2016-11-30 | PHASE4 |
| NCT03432793 | COMPLETED | Drug Drug Interaction (DDI) |
Theravance Biopharma |
2018-02-28 | PHASE1 |
| NCT03398421 | COMPLETED | Pulmonary Disease, Chronic Obstructive |
GlaxoSmithKline |
2018-01-17 | PHASE1 |
| NCT02253420 | COMPLETED | Medical Oncology |
Bayer |
2014-10-08 | PHASE1 |
| NCT03340662 | COMPLETED | Healthy Volunteer |
Celgene |
2017-11-09 | PHASE1 |
| NCT02130661 | WITHDRAWN | Alzheimer's Disease |
GlaxoSmithKline |
2017-10 | PHASE1 |
| NCT03346837 | COMPLETED | Malignancies Multiple |
Bristol-Myers Squibb |
2017-11-22 | PHASE1 |
| NCT03077607 | COMPLETED | Advanced Solid Tumors |
Pfizer |
2016-11-07 | PHASE1 |
| NCT03259542 | COMPLETED | Drug Interaction Potentiation; Healthy |
Corcept Therapeutics |
2017-08-09 | PHASE1 |
| NCT04080596 | COMPLETED | Drug Interaction |
Hua Medicine Limited |
2017-10-13 | PHASE1 |
| NCT03264079 | COMPLETED | Healthy Volunteers |
Biogen |
2017-10-16 | PHASE1 |
| NCT03301181 | COMPLETED | Healthy Volunteers: Asian, Non-Asian |
BeiGene |
2017-09-18 | PHASE1 |
| NCT02735356 | COMPLETED | Skin Basal Cell Carcinoma |
Jean Yuh Tang |
2016-05-05 | EARLY_PHASE1 |
| NCT03121664 | COMPLETED | Healthy |
Pfizer |
2017-04-07 | PHASE1 |
| NCT03119077 | TERMINATED | Polycystic Ovary Syndrome |
Bayer |
2017-04-27 | PHASE1 |
| NCT03222310 | COMPLETED | Healthy Volunteers |
Hoffmann-La Roche |
2017-07-18 | PHASE1 |
| NCT03135106 | COMPLETED | Healthy |
Janssen Research & Development, LLC |
2017-04-14 | PHASE1 |
| NCT03209648 | COMPLETED | Healthy Participants |
Debiopharm International SA |
2017-06-14 | PHASE1 |
| NCT03213145 | COMPLETED | NASH - Nonalcoholic Steatohepatitis |
Enanta Pharmaceuticals, Inc |
2017-07-11 | PHASE1 |
| NCT03173170 | COMPLETED | Healthy Participants |
Takeda |
2017-05-31 | PHASE1 |
| NCT02989389 | COMPLETED | Healthy |
Eli Lilly and Company |
2016-12-12 | PHASE1 |
| NCT03161405 | COMPLETED | Healthy Participants |
Millennium Pharmaceuticals, Inc. |
2017-06-05 | PHASE1 |
| NCT02440009 | COMPLETED | Allergic Bronchopulmonary Aspergillosis |
Post Graduate Institute of Medical Education and Research, Chandigarh |
2014-05 | PHASE2; PHASE3 |
| NCT03174041 | COMPLETED | Healthy Participants |
Genentech, Inc. |
2017-04-18 | PHASE1 |
| NCT02122770 | COMPLETED | Advanced Solid Tumors |
Millennium Pharmaceuticals, Inc. |
2014-04-01 | PHASE1 |
| NCT03138785 | UNKNOWN | Treatment |
Farabi Eye Hospital |
2015-01-01 | |
| NCT03116893 | COMPLETED | Healthy |
Boehringer Ingelheim |
2017-04-19 | PHASE1 |
| NCT01787331 | COMPLETED | Prostate Adenocarcinoma; Recurrent Prostate Carcinoma; Stage I Prostate Adenocarcinoma AJCC v7; Stage II Prostate Adenocarcinoma AJCC v7; Stage III Prostate Adenocarcinoma AJCC v7 |
University of California, San Francisco |
2013-10-29 | PHASE2 |
| NCT02817100 | COMPLETED | Clinical Trials, Phase I as Topic |
Bayer |
2016-07-22 | PHASE1 |
| NCT03048110 | COMPLETED | Biological Availability |
Bayer |
2017-02-15 | PHASE1 |
| NCT02838264 | COMPLETED | Healthy |
Pfizer |
2016-08-16 | PHASE1 |
| NCT02975037 | COMPLETED | Healthy |
Seoul National University Hospital |
2017-02-06 | PHASE1 |
| NCT02836171 | COMPLETED | Neoplasms |
Jiangsu HengRui Medicine Co., Ltd. |
2016-07 | PHASE1 |
| NCT02706535 | COMPLETED | Drug Interactions; Neoplasms |
GlaxoSmithKline |
2016-05-05 | PHASE1 |
| NCT02828241 | COMPLETED | Rosacea |
Dr. Reddy's Laboratories Limited |
2016-07 | PHASE2 |
| NCT02755857 | COMPLETED | Neutropenia |
Mayne Pharma International Pty Ltd |
2016-07 | PHASE2 |
| NCT02567773 | COMPLETED | Cachexia |
GlaxoSmithKline |
2015-09 | PHASE1 |
| NCT02883114 | COMPLETED | Healthy |
Pfizer |
2016-09 | PHASE1 |
| NCT02831972 | COMPLETED | Healthy |
Agios Pharmaceuticals, Inc. |
2016-06 | PHASE1 |
| NCT02820935 | COMPLETED | Pharmacokinetics |
Celgene Corporation |
2016-07 | PHASE1 |
| NCT02633709 | COMPLETED | Spinal Muscular Atrophy |
Hoffmann-La Roche |
2016-01-07 | PHASE1 |
| NCT02809768 | COMPLETED | Healthy Participants |
Eisai Inc. |
2016-04 | PHASE1 |
| NCT02807909 | COMPLETED | Thrombosis |
Bristol-Myers Squibb |
2016-07 | PHASE1 |
| NCT02729467 | COMPLETED | Healthy |
Janssen Research & Development, LLC |
2016-03 | PHASE1 |
| NCT02790671 | COMPLETED | Pharmacokinetics |
Daiichi Sankyo |
2016-05 | PHASE1 |
| NCT02420782 | COMPLETED | Healthy Volunteers |
Astellas Pharma Europe B.V. |
2015-05 | PHASE1 |
| NCT02653872 | COMPLETED | Healthy Subjects |
AstraZeneca |
2016-01-22 | PHASE1 |
| NCT02698267 | COMPLETED | Neuropathic Pain |
Biogen |
2016-02 | PHASE1 |
| NCT06004947 | COMPLETED | Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis |
Amgen |
2016-01-14 | PHASE1 |
| NCT02457351 | COMPLETED | Medical Oncology |
Bayer |
2015-07 | PHASE1 |
| NCT02323334 | COMPLETED | Healthy Volunteers; Alzheimer Disease |
Eli Lilly and Company |
2014-12 | PHASE1 |
| NCT02513446 | COMPLETED | Healthy |
Boehringer Ingelheim |
2015-09-29 | PHASE1 |
| NCT01576315 | COMPLETED | Cystic Fibrosis; Aspergillus Infections |
Rennes University Hospital |
2014-06 | PHASE2 |
| NCT01974687 | COMPLETED | Chronic Hepatitis C |
Merck Sharp & Dohme LLC |
2013-10-31 | PHASE1; PHASE2 |
| NCT02341638 | COMPLETED | Thrombosis |
Bristol-Myers Squibb |
2014-09 | PHASE1 |
| NCT02456129 | COMPLETED | Clinical Trial, Phase I |
Bayer |
2015-07 | PHASE1 |
| NCT02475746 | WITHDRAWN | Healthy |
Pfizer |
2015-07 | PHASE1 |
| NCT02401295 | COMPLETED | Relapsed Multiple Myeloma |
University of Iowa |
2015-05 | PHASE1 |
| NCT02402595 | COMPLETED | Healthy |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2015-03-01 | PHASE1 |
| NCT02470832 | COMPLETED | Healthy Patient Study |
Hoffmann-La Roche |
2015-05 | PHASE1 |
| NCT02440841 | COMPLETED | Nocturia |
Vantia Ltd |
2015-05 | PHASE1 |
| NCT02455856 | COMPLETED | Healthy |
Janssen Cilag N.V./S.A. |
2015-05-18 | PHASE1 |
| NCT02054793 | WITHDRAWN | Prostate Cancer; Castration-resistant Prostate Cancer |
Emmanuel Antonarakis, MD |
2014-06 | PHASE1; PHASE2 |
| NCT02365571 | COMPLETED | Healthy Participants |
Eli Lilly and Company |
2015-02 | PHASE1 |
| NCT02157883 | COMPLETED | Advanced Non Small Cell Lung Cancer; Advanced (Inoperable) Non Small Cell Lung Cancer |
AstraZeneca |
2014-11-06 | PHASE1 |
| NCT02300259 | COMPLETED | Healthy Volunteers |
Eli Lilly and Company |
2014-11 | PHASE1 |
| NCT02328443 | COMPLETED | Healthy |
Seoul National University Hospital |
2014-01 | PHASE1 |
| NCT02370615 | COMPLETED | Japanese Healthy Adult Males |
Takeda |
2015-02 | PHASE1 |
| NCT02341482 | COMPLETED | Healthy |
Biogen |
2015-02-05 | PHASE1 |
| NCT02259010 | COMPLETED | Advanced Solid Tumors; Relapsed/Refractory Lymphoma |
Millennium Pharmaceuticals, Inc. |
2014-10-22 | PHASE1 |
| NCT02342717 | COMPLETED | Healthy |
Boehringer Ingelheim |
2015-01 | PHASE1 |
| NCT02199431 | COMPLETED | Healthy |
H. Lundbeck A/S |
2014-07 | PHASE1 |
| NCT02248259 | COMPLETED | Healthy |
Boehringer Ingelheim |
2014-10-08 | PHASE1 |
| NCT02230033 | COMPLETED | Healthy |
Aragon Pharmaceuticals, Inc. |
2014-09 | PHASE1 |
| NCT02272764 | COMPLETED | Pharmacokinetics |
Alkermes, Inc. |
2014-10 | PHASE1 |
| NCT02155504 | COMPLETED | Healthy Volunteers; Pharmacokinetics of ASP3700 |
Astellas Pharma Europe B.V. |
2014-05 | PHASE1 |
| NCT02319148 | COMPLETED | Healthy Volunteers |
Pfizer |
2014-07 | PHASE1 |
| NCT02197884 | COMPLETED | Healthy |
Janssen Research & Development, LLC |
2014-07 | PHASE1 |
| NCT02045849 | COMPLETED | Infections, Bacterial |
GlaxoSmithKline |
2014-01-28 | PHASE1 |
| NCT02118909 | COMPLETED | Healthy Volunteers; Non-smokers |
Helsinn Healthcare SA |
2014-05 | PHASE1 |
| NCT02131298 | COMPLETED | Healthy |
Pfizer |
2014-05 | PHASE1 |
| NCT02093728 | COMPLETED | Solid Tumours |
AstraZeneca |
2014-04 | PHASE1 |
| NCT02175407 | COMPLETED | Pharmacokinetics; DDI (Drug-Drug Interaction); Healthy Subjects |
Astellas Pharma Europe B.V. |
2014-04 | PHASE1 |
| NCT02100553 | COMPLETED | Healthy |
Pfizer |
2014-04 | PHASE1 |
| NCT02122692 | COMPLETED | Healthy Volunteers |
H. Lundbeck A/S |
2014-03 | PHASE1 |
| NCT01772563 | COMPLETED | Neoplasms |
Boehringer Ingelheim |
2013-02-04 | PHASE1 |
| NCT04901923 | COMPLETED | Healthy Participants |
Acerta Pharma BV |
2014-03-15 | PHASE1 |
| NCT02044393 | COMPLETED | Healthy |
Boehringer Ingelheim |
2014-01 | PHASE1 |
| NCT02085967 | COMPLETED | Healthy Subjects |
Eisai Inc. |
2014-02 | PHASE1 |
| NCT02055703 | COMPLETED | Healthy Subjects |
Eisai Inc. |
2014-01 | PHASE1 |
| NCT01752023 | TERMINATED | Non-small Cell Lung Cancer Metastatic |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2013-03 | PHASE2 |
| NCT01900028 | COMPLETED | Solid Tumours |
AstraZeneca |
2013-10 | PHASE1 |
| NCT01344681 | COMPLETED | Febrile Neutropenia; Hematological Diseases |
Yonsei University |
2011-06 | PHASE2 |
| NCT02065739 | COMPLETED | Healthy |
Janssen Pharmaceutica N.V., Belgium |
2014-01 | PHASE1 |
| NCT02010970 | COMPLETED | Healthy Volunteers; Pharmacologic Action |
AstraZeneca |
2013-12 | PHASE1 |
| NCT00588016 | COMPLETED | Sinusitis |
Mayo Clinic |
2007-04 | PHASE1 |
| NCT01967979 | COMPLETED | Healthy Volunteer |
Hoffmann-La Roche |
2013-10 | PHASE1 |
| NCT01929876 | COMPLETED | Healthy Participants |
Genentech, Inc. |
2013-07 | PHASE1 |
| NCT01768663 | COMPLETED | Cystic Fibrosis |
Vertex Pharmaceuticals Incorporated |
2013-01 | PHASE1 |
| NCT01814709 | COMPLETED | Healthy Volunteer |
Genentech, Inc. |
2013-04 | PHASE1 |
| NCT01772290 | COMPLETED | Healthy Volunteer |
Genentech, Inc. |
2013-02 | PHASE1 |
| NCT01795937 | COMPLETED | Healthy |
Boehringer Ingelheim |
2013-02 | PHASE1 |
| NCT01321827 | COMPLETED | Allergic Bronchopulmonary Aspergillosis |
Post Graduate Institute of Medical Education and Research, Chandigarh |
2011-04 | PHASE2; PHASE3 |
| NCT00769600 | TERMINATED | Recurrent Non Small Cell Lung Cancer |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2008-11 | PHASE2 |
| NCT01568411 | COMPLETED | Healthy |
Glycyx Therapeutics |
2012-04 | PHASE1 |
| NCT00798135 | COMPLETED | Breast Neoplasms; Neoplasm Metastasis |
Indiana University |
2008-11 | |
| NCT01392430 | COMPLETED | HIV Infection |
Chiang Mai University |
2009-06 | |
| NCT01913379 | COMPLETED | Healthy Subjects; Pharmacokinetics; Drug-Drug Interaction |
Astellas Pharma Europe B.V. |
2011-08 | PHASE1 |
| NCT01259336 | COMPLETED | Chronic Cavitary Pulmonary Aspergillosis |
Post Graduate Institute of Medical Education and Research, Chandigarh |
2010-07 | PHASE4 |
| NCT00887458 | COMPLETED | Prostate Cancer |
Johns Hopkins University |
2009-07 | PHASE2 |
| NCT01450683 | TERMINATED | Prostate Cancer; Prostatic Neoplasms; Castrate-resistant Prostate Cancer (CRPC); Androgen-insensitive Prostate Cancer; Hormone-refractory Prostate Cancer; Metastatic Disease |
Stanford University |
2010-09 | PHASE2 |
| NCT00673309 | COMPLETED | Burns |
The University of Texas Medical Branch, Galveston |
2000-07 | PHASE2; PHASE3 |
| NCT01108094 | COMPLETED | Basal Cell Carcinoma (BCC); Skin Cancer |
Stanford University |
2010-04 | PHASE2 |
| NCT01409018 | COMPLETED | Pediatric, Cancer |
Seoul National University Hospital |
2009-06 | PHASE1 |
| NCT01282879 | TERMINATED | Graft vs Host Disease |
Samsung Medical Center |
2009-12 | PHASE4 |
| NCT01160952 | UNKNOWN | Hematological Diseases; Allogeneic Stem Cell Transplantation |
Guangzhou General Hospital of Guangzhou Military Command |
2009-05 | PHASE2 |
| NCT01214941 | COMPLETED | Pharmacokinetics; Pharmacodynamics |
Turku University Hospital |
2010-09 | PHASE4 |
| NCT01198236 | COMPLETED | Invasive Fungal Infection |
Zhejiang University |
2008-07 | PHASE4 |
| NCT00528190 | COMPLETED | Cystic Fibrosis |
Ottawa Hospital Research Institute |
2007-10 | PHASE4 |
| NCT00791219 | COMPLETED | Onychomycosis |
Halcygen Pharmaceuticals Limited |
2008-11 | PHASE2 |
| NCT00787917 | TERMINATED | Cystic Fibrosis; Allergic Bronchopulmonary Aspergillosis |
Novartis Pharmaceuticals |
2008-11 | PHASE4 |
| NCT00794703 | COMPLETED | Fungemia; Fungal Infections |
Astellas Pharma Inc |
2008-11 | PHASE3 |
| NCT00871728 | COMPLETED | Onychomycosis, Toe |
Janssen Korea, Ltd., Korea |
2007-01 | PHASE4 |
| NCT00289991 | COMPLETED | Antifungal Prophylaxis of Invasive Fungal Infections |
Pfizer |
2006-03 | PHASE3 |
| NCT01823289 | COMPLETED | Pulmonary Fungal Infection |
Xian-Janssen Pharmaceutical Ltd. |
2007-06 | PHASE4 |
| NCT00356915 | COMPLETED | Onychomycosis |
Stiefel, a GSK Company |
2006-07 | PHASE3 |
| NCT00695071 | COMPLETED | Healthy |
Stiefel, a GSK Company |
2008-06 | PHASE1 |
| NCT00336531 | COMPLETED | Neuroblastoma; Brain Tumor; Retinoblastoma; Wilms Tumor; Mycoses |
Samsung Medical Center |
2006-04 | PHASE4 |
| NCT00045942 | COMPLETED | Acute Myeloid Leukemia; Myelodysplastic Syndromes |
Novartis Pharmaceuticals |
2002-01-30 | PHASE1; PHASE2 |
| NCT00895453 | COMPLETED | Vulvovaginal Candidiasis |
Medical University of Vienna |
2000-05 | |
| NCT00079222 | COMPLETED | Cancer |
Jonsson Comprehensive Cancer Center |
2003-11 | |
| NCT02264041 | COMPLETED | Healthy |
Boehringer Ingelheim |
2004-01 | PHASE1 |
| NCT00003883 | COMPLETED | Cancer |
Fred Hutchinson Cancer Center |
1998-10 | PHASE3 |
| NCT00000639 | COMPLETED | Meningitis, Cryptococcal; HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
||
| NCT00012467 | COMPLETED | Meningitis, Cryptococcal; HIV Infections |
InterMune |
2000-01 | PHASE2 |
| NCT00002370 | COMPLETED | HIV Infections |
Janssen, LP |
||
| NCT00002341 | COMPLETED | Candidiasis, Oral; HIV Infections |
Janssen, LP |
||
| NCT00005668 | COMPLETED | Aspergillosis; Lung Diseases, Fungal |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00002159 | COMPLETED | HIV Infections; Histoplasmosis; Blastomycosis |
Janssen, LP |
PHASE3 | |
| NCT00000992 | COMPLETED | HIV Infections; Histoplasmosis |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00002132 | COMPLETED | Candidiasis, Esophageal; HIV Infections |
Janssen Pharmaceuticals |
||
| NCT00001280 | COMPLETED | Mycoses |
National Institute of Allergy and Infectious Diseases (NIAID) |
1991-01 | PHASE2 |
| NCT00002438 | COMPLETED | HIV Infections; Histoplasmosis |
Janssen, LP |
||
| NCT00004811 | COMPLETED | Histoplasmosis; Sporotrichosis; Blastomycosis |
National Center for Research Resources (NCRR) |
1985-03 | PHASE1; PHASE2 |
| NCT00000975 | COMPLETED | HIV Infections; Histoplasmosis |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00002133 | COMPLETED | Candidiasis, Oral; HIV Infections |
Janssen, LP |
(data from https://clinicaltrials.gov, updated on 2026-05-08)
Check the
Itraconazole
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
Note: Technical data last updated: Sep 1, 2026.